BioTechne Corp (TECH)
(Delayed Data from NSDQ)
$73.52 USD
-1.26 (-1.68%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $73.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.52 USD
-1.26 (-1.68%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $73.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Is Techne (TECH) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Techne (TECH) possesses solid growth attributes, which could help it handily outperform the market.
QIAGEN's (QGEN) Kits Hit New Milestone for Sample Preparation
by Zacks Equity Research
QIAGEN's (QGEN) consumables kits have been utilized to process more than 3 billion biological samples, emphasizing on its leading position in sample preparation.
Can Bio-Techne (TECH) Stock Continue to Grow Earnings?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Bio-Techne (TECH).
Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPMD
QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.
ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.
Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.
Techne (TECH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 11.31% and 4.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.
Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.
CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.
Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Techne (TECH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.
Why the Earnings Surprise Streak Could Continue for Techne (TECH)
by Zacks Equity Research
Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ALXN vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study
by Zacks Equity Research
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal
by Zacks Equity Research
QIAGEN (QGEN) and Sysmex collaborate to develop and commercialize cancer companion diagnostics.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.
Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment
by Zacks Equity Research
Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
by Zacks Equity Research
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.
Geron (GERN) Soars on Imetelstat Data for Myelofibrosis
by Zacks Equity Research
Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM
by Zacks Equity Research
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.